Patents Assigned to Rosalind Franklin University of Medicine and Science
  • Patent number: 10544417
    Abstract: The present disclosure relates generally to compounds comprising oligonucleotides complementary to a cystic fibrosis transmembrane conductance regulator (CFTR) RNA transcript. Certain such compounds are useful for hybridizing to a CFTR RNA transcript, including but not limited to a CFTR RNA transcript in a cell. In certain embodiments, such hybridization results in modulation of splicing of the CFTR transcript. In certain embodiments, such compounds are used to treat one or more symptoms associated with Cystic Fibrosis.
    Type: Grant
    Filed: December 8, 2017
    Date of Patent: January 28, 2020
    Assignee: Rosalind Franklin University of Medicine and Science
    Inventor: Michelle L. Hastings
  • Patent number: 10525076
    Abstract: The present disclosure relates generally to compounds comprising oligonucleotides complementary to a cystic fibrosis transmembrane conductance regulator (CFTR) RNA transcript. Certain such compounds are useful for hybridizing to a CFTR RNA transcript, including but not limited to a CFTR RNA transcript in a cell. In certain embodiments, such hybridization results in modulation of splicing of the CFTR transcript. In certain embodiments, such compounds are used to treat one or more symptoms associated with Cystic Fibrosis.
    Type: Grant
    Filed: December 8, 2017
    Date of Patent: January 7, 2020
    Assignee: Rosalind Franklin University of Medicine and Science
    Inventor: Michelle L. Hastings
  • Patent number: 10472634
    Abstract: The present invention provides compounds comprising oligonucleotides complementary to an LRP8 transcript. Certain such compounds are useful for hybridizing to an LRP8 transcript, including but not limited, to an LRP8 transcript in a cell. In certain embodiments, such hybridization results in modulation of splicing of the LRP8 transcript. In certain embodiments, such hybridization results in an increase in inclusion of exon 19 in the LRP8 mRNA transcript. In certain embodiments, such compounds are used to treat Alzheimer's Disease.
    Type: Grant
    Filed: June 4, 2015
    Date of Patent: November 12, 2019
    Assignees: Ionis Pharmaceuticals, Inc., Rosalind Franklin University of Medicine and Science
    Inventors: Frank Rigo, Michelle L. Hastings
  • Patent number: 10370667
    Abstract: The present disclosure relates generally to compounds comprising oligonucleotides complementary to a Leucine-Rich-Repeat-Kinase (LRRK2) RNA transcript. Certain such compounds are useful for hybridizing to a LRRK2 RNA transcript, including but not limited to a LRRK2 RNA transcript in a cell. In certain embodiments, such hybridization results in modulation of splicing of the LRRK2 transcript. In certain embodiments, such compounds are used to treat one or more symptoms associated with Parkinson's disease.
    Type: Grant
    Filed: December 11, 2017
    Date of Patent: August 6, 2019
    Assignees: Rosalind Franklin University Of Medicine And Science, The McLean Hospital Corporation
    Inventors: Michelle L. Hastings, Ole Isacson, Joanna A. Korecka-Roet
  • Patent number: 10351608
    Abstract: The present invention provides a method for treating a human patient with a pathology by administering to the subject an effective amount of an agent selected from the group of: native full-length CCN3 proteins; analog CCN3 full-length proteins with native cysteine residues substituted by a replacement amino acid; CCNp native peptide fragments having from about 12 to about 20 amino acids; analog CCNp peptide fragments with native cysteine residues substituted with a replacement amino acid; and combinations thereof.
    Type: Grant
    Filed: August 7, 2015
    Date of Patent: July 16, 2019
    Assignee: Rosalind Franklin University of Medicine and Science
    Inventor: Bruce L. Riser
  • Patent number: 10070648
    Abstract: Disclosed herein are photodynamic insecticide methods and compositions for the control or reduction of insect populations comprising the use of photosensitizer compounds in combination with light.
    Type: Grant
    Filed: April 10, 2017
    Date of Patent: September 11, 2018
    Assignees: Rosalind Franklin University of Medicine and Science, National Taiwan University
    Inventors: Kwang Poo Chang, Bala Krishna Kolli, Shin-Hong Shiao
  • Patent number: 10028906
    Abstract: A kit for treating a human patient with a solid tumor with a desmoplasia associated therewith having: (1) a container of and effective amount of a CCNp37 (SEQ ID No. 37), CCNp38 (SEQ ID No. 38) or a combination of CCNp37 and CCNp38 (SEQ ID Nos. 37 and 38); (2) a container of an effective amount of a chemotherapeutic agent or an immunotherapeutic agent; and (3) instructions for administering these components which can involve a pretreatment with the CCNp37 (SEQ ID No. 37), CCNp38 (SEQ ID No. 38) or a combination of CCNp37 and CCNp38 (SEQ ID Nos. 37 and 38) to a patient in need thereof.
    Type: Grant
    Filed: March 22, 2017
    Date of Patent: July 24, 2018
    Assignee: Rosalind Franklin University of Medicine and Science
    Inventor: Bruce L. Riser
  • Patent number: 10011578
    Abstract: Disclosed herein are methods and compositions comprising compounds capable of normalizing neuronal calcium dyshomeostasis. Also disclosed are methods comprising these compounds for treating neuronal or neurological disorders, including Alzheimer's disease, Parkinson's disease, Huntington's disease, fronto-temporal dementia, Pick's disease, chronic traumatic encepholopathy, traumatic brain injury, stroke, cerebellar ataxia, multiple sclerosis, Down syndrome, and aging-related CNS disorders.
    Type: Grant
    Filed: August 8, 2017
    Date of Patent: July 3, 2018
    Assignee: Rosalind Franklin University of Medicine and Science
    Inventors: Grace E. Stutzmann, Russell Dahl, Christopher H. Kaiho
  • Patent number: 9970056
    Abstract: Network-based meta-analysis of four independent microarray studies identified the hepatocyte nuclear factor (HNF4A), a transcription factor associated with gluconeogenesis and diabetes, as a central regulatory hub gene upregulated in blood of PD patients. In parallel, the polypyrimidine tract binding protein 1 (PTBP1), involved in the stabilization and mRNA translation of insulin, was identified as the most downregulated gene. Using both markers, PD patients were classified with 90% sensitivity and 80% specificity. Longitudinal performance analysis demonstrated that relative abundance of HNF4A and PTBP1 mRNAs significantly decreased and increased, respectively, in PD patients during 3 years follow up period. The inverse regulation of HNF4A and PTBP1 provides a molecular rationale for the altered insulin signaling observed in PD patients. The longitudinally dynamic biomarkers identified in this study may be useful for monitoring disease-modifying therapies for PD.
    Type: Grant
    Filed: September 30, 2015
    Date of Patent: May 15, 2018
    Assignee: Rosalind Franklin University of Medicine and Science
    Inventors: Judith Ann Potashkin, Jose Alfredo Santiago
  • Publication number: 20180117073
    Abstract: The present disclosure relates generally to compounds comprising oligonucleotides complementary to a cystic fibrosis transmembrane conductance regulator (CFTR) RNA transcript. Certain such compounds are useful for hybridizing to a CFTR RNA transcript, including but not limited to a CFTR RNA transcript in a cell. In certain embodiments, such hybridization results in modulation of splicing of the CFTR transcript. In certain embodiments, such compounds are used to treat one or more symptoms associated with Cystic Fibrosis.
    Type: Application
    Filed: December 8, 2017
    Publication date: May 3, 2018
    Applicant: Rosalind Franklin University of Medicine and Science
    Inventor: Michelle L. Hastings
  • Publication number: 20180119152
    Abstract: The present disclosure relates generally to compounds comprising oligonucleotides complementary to a cystic fibrosis transmembrane conductance regulator (CFTR) RNA transcript. Certain such compounds are useful for hybridizing to a CFTR RNA transcript, including but not limited to a CFTR RNA transcript in a cell. In certain embodiments, such hybridization results in modulation of splicing of the CFTR transcript. In certain embodiments, such compounds are used to treat one or more symptoms associated with Cystic Fibrosis.
    Type: Application
    Filed: December 8, 2017
    Publication date: May 3, 2018
    Applicant: Rosalind Franklin University of Medicine and Science
    Inventor: Michelle L. HASTINGS
  • Patent number: 9840710
    Abstract: The present disclosure relates generally to compounds comprising oligonucleotides complementary to a Leucine-Rich-Repeat-Kinase (LRRK2) RNA transcript. Certain such compounds are useful for hybridizing to a LRRK2 RNA transcript, including but not limited to a LRRK2 RNA transcript in a cell. In certain embodiments, such hybridization results in modulation of splicing of the LRRK2 transcript. In certain embodiments, such compounds are used to treat one or more symptoms associated with Parkinson's disease.
    Type: Grant
    Filed: November 11, 2016
    Date of Patent: December 12, 2017
    Assignees: Rosalind Franklin University of Medicine and Science, The McLean Hospital Corporation
    Inventors: Michelle L. Hastings, Ole Isacson, Joanna A. Korecka-Roet
  • Patent number: 9840709
    Abstract: The present disclosure relates generally to compounds comprising oligonucleotides complementary to a cystic fibrosis transmembrane conductance regulator (CFTR) RNA transcript. Certain such compounds are useful for hybridizing to a CFTR RNA transcript, including but not limited to a CFTR RNA transcript in a cell. In certain embodiments, such hybridization results in modulation of splicing of the CFTR transcript. In certain embodiments, such compounds are used to treat one or more symptoms associated with Cystic Fibrosis.
    Type: Grant
    Filed: February 17, 2016
    Date of Patent: December 12, 2017
    Assignee: Rosalind Franklin University of Medicine and Science
    Inventor: Michelle L. Hastings
  • Patent number: 9839389
    Abstract: The present disclosure provides a device for testing the strength of a human foot. The device includes a substantially planar member having a top surface and a bottom surface. The device also includes a foot-engaging member moveable along the top surface substantially planar member from a first position to a second position. In addition, the device includes a force sensor fixed with respect to the substantially planar member, where the force sensor resists movement between the first position and the second position. Further, the device includes a tension bearing element connecting the foot-engaging member to the force sensor.
    Type: Grant
    Filed: April 17, 2015
    Date of Patent: December 12, 2017
    Assignee: Rosalind Franklin University of Medicine and Science
    Inventor: Karen Marie Stevens
  • Patent number: 9827478
    Abstract: The present disclosure is directed to a body-worn sensor-based system for evaluating the biomechanics and the motor adaptation characteristics of postural control during a sport activity such as a golf swing. Various embodiments use sensors such as accelerometers, gyroscopes, and magnetometers to measure the three-dimensional motion of ankle and hip joints. In several embodiments, additional sensors attached to other body segments are used to improve the accuracy of the data or detect particular instants during the swing (e.g., top of back swing, instant of the maximum speed of arm, and instant of ball impact). In a golf embodiment, the system combines the measured data in conjunction with a biomechanical model of the human body to: (1) estimate the two-dimensional sway of the golfer's center of mass; (2) quantify and evaluate the golfer's balance via his/her postural compensatory strategy; and (3) provide visual feedback to the golfer for improving dynamic postural control.
    Type: Grant
    Filed: February 6, 2015
    Date of Patent: November 28, 2017
    Assignees: BOISENSICS LLC, ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE
    Inventors: Bijan Najafi, James Stanley Wrobel, Ali-Reza Boloori
  • Publication number: 20170268000
    Abstract: The present invention provides compounds comprising oligonucleotides complementary to a CLN3 transcript. Certain such compounds are useful for hybridizing to a CLN3 transcript, including but not limited to a CLN3 transcript in a cell. In certain embodiments, such hybridization results in modulation of splicing of the CLN3 transcript. In certain embodiments, such compounds are used to treat one or more symptoms associated with Batten Disease.
    Type: Application
    Filed: December 2, 2014
    Publication date: September 21, 2017
    Applicants: Ionis Pharmaceuticals, Inc., Rosalind Franklin University of Medicine and Science
    Inventors: Frank RIGO, Michelle L. HASTINGS
  • Patent number: 9753042
    Abstract: The present invention provides a kit for determining male fertility including a container system containing a plurality of enzyme-linked antibodies one of each capable of binding to analytes Atp6v0a2, G-CSF, MIP 1?, and MCP-1. The kit further includes suitable packaging and a set of instructions for using the enzyme-linked antibodies with a seminal sample to determine the fertility of the sample.
    Type: Grant
    Filed: April 22, 2014
    Date of Patent: September 5, 2017
    Assignee: Rosalind Franklin University of Medicine and Science
    Inventor: Kenneth Beaman
  • Patent number: 9725429
    Abstract: Disclosed herein are methods and compositions comprising compounds of formula (I) capable of normalizing neuronal calcium dyshomeostasis. Also disclosed are methods comprising these compounds for treating neuronal or neurological disorders, including Alzheimer's disease, Parkinson's disease, Huntington's disease, fronto-temporal dementia, Pick's disease, chronic traumatic encepholopathy, traumatic brain injury, stroke, cerebellar ataxia, multiple sclerosis, Down syndrome, and aging-related CNS disorders.
    Type: Grant
    Filed: May 19, 2015
    Date of Patent: August 8, 2017
    Assignee: Rosalind Franklin University of Medicine and Science
    Inventors: Grace E. Stutzmann, Russell Dahl, Christopher H. Kaiho
  • Publication number: 20170191066
    Abstract: The present invention provides compounds comprising oligonucleotides complementary to an LRP8 transcript. Certain such compounds are useful for hybridizing to an LRP8 transcript, including but not limited, to an LRP8 transcript in a cell. In certain embodiments, such hybridization results in modulation of splicing of the LRP8 transcript. In certain embodiments, such hybridization results in an increase in inclusion of exon 19 in the LRP8 mRNA transcript. In certain embodiments, such compounds are used to treat Alzheimer's Disease.
    Type: Application
    Filed: June 4, 2015
    Publication date: July 6, 2017
    Applicants: Ionis Pharmaceuticals, Inc., Rosalind Franklin University of Medicine and Science
    Inventors: Frank Rigo, Michelle L. Hastings
  • Patent number: 9556434
    Abstract: The present invention provides a method for treating Usher's syndrome in a human subject including administering to the human subject an oligonucleotide having 8 to 30 linked nucleosides having a nucleobase sequence comprising a complementary region comprising at least 8 contiguous nucleobases complementary to a target region of equal length within exon 3 of an Usher RNA transcript.
    Type: Grant
    Filed: May 6, 2015
    Date of Patent: January 31, 2017
    Assignee: Rosalind Franklin University of Medicine and Science
    Inventor: Michelle L Hastings